Disease Science Footnotes/Bibliography
Bibliography
1.Mitchel, T., Geetha, M., James, E. V., Rebecca, H. R. & Judy, B. D. H. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. (2018). https://www.frontiersin.org/articles/10.3389/fphys.2018.00114/full
2.Rameez, H., Nasir, J. & Sangdun, Choi. “The roles of the N. inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions. (2020). https://www.mdpi.com/2073-4425/11/2/131
3.Chi, T. et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. (2021). https://www.sciencedirect.com/science/article/pii/S135964462100101X
4.David, M. H. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease. (2019). https://link.springer.com/chapter/10.1007/978-981-32-9358-8_16
5.Luwen, W. et al. Rab10 phosphorylation is a prominent pathological feature in Alzheimer’s disease. (2018). https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180023
6.Pietro, A. & Laura, Cogli. “The role of rab proteins in neuronal cells and in the trafficking of neurotrophin receptors The role of rab proteins in neuronal cells and in the trafficking of neurotrophin receptors. (2014). https://www.mdpi.com/2077-0375/4/4/642
7.Kate, L., David, J. K., Tiago, F. O. & Flaviano, Giorgini. “Therapeutic targeting of R. Gtp. R. for A. disease Therapeutic targeting of Rab GTPases: Relevance for Alzheimer’s disease. (2022). https://www.mdpi.com/2227-9059/10/5/1141
8.Anca, I., Camilla, I. S., Vivianne, M., Georg, S. & Lars, Klareskog. “Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. (2017). https://www.nature.com/articles/nrrheum.2016.200
9.Na, L., Keshav, R. S. & Lihua, D. Role of NLRP3 inflammasome in rheumatoid arthritis. (2022). https://www.frontiersin.org/articles/10.3389/fimmu.2022.931690/full
10.Chengyu, Y., Jianqiao, F. & Boyi, L. The NLRP3 inflammasome: an emerging therapeutic target for chronic pain. (2021). https://link.springer.com/article/10.1186/s12974-021-02131-0
11.Fengxian, L. et al. The inflammasome as a target for pain therapy. (2016). https://academic.oup.com/bja/article-abstract/117/6/693/2671120
12.Mikkael, A. & Justin, Taylor. “Diagnosis and treatment of myelodysplastic syndromes: a review Diagnosis and treatment of myelodysplastic syndromes: a review. (2022). https://jamanetwork.com/journals/jama/article-abstract/2795886
13.Howard, S. O., Michael, H. & Drorit, Neumann. “The lower risk M. patient at risk of rapid progression The lower risk MDS patient at risk of rapid progression. (2010). https://www.sciencedirect.com/science/article/pii/S0145212610002821
14.Mengjia, H., Yukai, L., Songling, H. & Junping, Wang. “Inflammasomes and the maintenance of hematopoietic homeostasis: new perspectives and opportunities Inflammasomes and the maintenance of hematopoietic homeostasis: new perspectives and opportunities. (2021). https://www.mdpi.com/1420-3049/26/2/309
15.Bofeng, L., Arnaud, J. K. K., Tengchuan, J. & Jinhui, T. Pharmacological inhibitors of the NLRP3 inflammasome. (2019). https://www.frontiersin.org/articles/10.3389/fimmu.2019.02538/full
16.Weiming, O., Chuanshu, Huang. “Inflammation & a, key event in cancer development Inflammation, a key event in cancer development. (2006). https://aacrjournals.org/mcr/article-abstract/4/4/221/284795
17.Do-Hee, K. & Young-Joon, Surh. “Dynamic roles of inflammasomes in inflammatory tumor microenvironment Dynamic roles of inflammasomes in inflammatory tumor microenvironment. (2021). https://www.nature.com/articles/s41698-021-00154-7
18.Ulrich, T. H., Hildegard, B., Olivier, B. & Sahil, A. Pyroptotic and necroptotic cell death in the tumor microenvironment and their potential to stimulate anti-tumor immune responses. (2021). https://www.frontiersin.org/articles/10.3389/fonc.2021.731598/full
19.Maria, G., Louis, B., Andreas, K., Aikaterini, H. & Panayotis, V. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression. (2022). https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.889075/full?trk=public_post_comment-text
20.Maria, S., Efthimios, D., Georgios, M. H., Dimitrios, B. & Georgia, Xiromerisiou. “Neurodegeneration and inflammation—an interesting interplay in P. disease Neurodegeneration and inflammation—an interesting interplay in Parkinson’s disease. (2020). https://www.mdpi.com/1422-0067/21/22/8421
21.Yu-He, Y., Nai-Hong, C. & Hong-Bo, W. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. (2019). https://www.sciencedirect.com/science/article/pii/S1567576918307641
22.Yiming, Z., Rui, L., Lingpeng, Z., Buqing, F. & Tianhua, Yan. “Salidroside ameliorates P. disease by inhibiting N. pyroptosis Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis. (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288953/
23.Jonathan, D., Jesper, F. H. & Charles, A. Dinarello. “Pharmacologic inhibition of N. reduces the levels of α-synuclein and protects dopaminergic neurons in a model of P. disease Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease. (2023). https://link.springer.com/article/10.1186/s12974-023-02830-w
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.